Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer

[1] Peraza MA(2018)Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab Regul Toxicol Pharmacol 95 236-243

[2] Rule KE(2016)A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers Cancer Chemother Pharmacol 77 839-846

[3] Shiue MHI(2019)PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin BioDrugs 33 555-570

[4] Finch GL(2008)), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study J Pharmacokinet Pharmacodyn 35 401-421

[5] Thibault S(2004)Likelihood based approaches to handling data below the quantification limit using NONMEM VI Comput Methods Progr Biomed 75 85-94

[6] Brown PR(2016)Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming Cancer Chemother Pharmacol 78 341-351

[7] Clarke DW(2008)Population pharmacokinetics of bevacizumab in cancer patients with external validation Cancer Chemother Pharmacol 62 779-786

[8] Leach MW(2018)Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemother Pharmacol 81 515-527

[9] Knight B(2012)Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach J Clin Pharmacol 52 1624-1644

[10] Rassam D(2016)Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human epoetin alfa and the biosimilar HX575 Eur J Clin Pharmacol 72 1343-1352

[1] Peraza MA(2018)Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab Regul Toxicol Pharmacol 95 236-243

[2] Rule KE(2016)A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers Cancer Chemother Pharmacol 77 839-846

[3] Shiue MHI(2019)PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin BioDrugs 33 555-570

[4] Finch GL(2008)), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study J Pharmacokinet Pharmacodyn 35 401-421

[5] Thibault S(2004)Likelihood based approaches to handling data below the quantification limit using NONMEM VI Comput Methods Progr Biomed 75 85-94

[6] Brown PR(2016)Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming Cancer Chemother Pharmacol 78 341-351

[7] Clarke DW(2008)Population pharmacokinetics of bevacizumab in cancer patients with external validation Cancer Chemother Pharmacol 62 779-786

[8] Leach MW(2018)Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemother Pharmacol 81 515-527

[9] Knight B(2012)Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach J Clin Pharmacol 52 1624-1644

[10] Rassam D(2016)Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human epoetin alfa and the biosimilar HX575 Eur J Clin Pharmacol 72 1343-1352